Loncastuximab tesirine is an CD19-targeted antibody–drug conjugate used for treatment of the relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL); it has proven to be a promising treatment for R/R DLBCL which is efficacious, has durable responses and is safe in this patient population [42,43]. The gene discussed is CD19; the disease is diffuse large B-cell lymphoma.